QRxPharma Ltd.  

(Public, ASX:QRX)   Watch this stock  
Find more results for QRX
0.0000 (0.00%)
Delayed:   2:54PM GMT+10
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range     -
52 week 0.00 - 0.07
Open     -
Vol. 0.00
Mkt cap 4.60M
P/E     -
Div/yield     -
EPS -0.01
Shares 164.19M
Beta     -
Inst. own     -
Aug 15, 2016
Interim 2016 QRxPharma Ltd Earnings Release (Estimated) Add to calendar
May 19, 2016
QRxPharma Ltd Annual Shareholders Meeting

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -24560.00% -59911.11%
Operating margin -28300.00% -70722.22%
EBITD margin - -64311.11%
Return on average assets -88.65% -74.55%
Return on average equity -108.02% -89.70%
CDP Score - -


SE 1 L 11, 100 Walker St
+61-2-84044139 (Phone)
+61-2-89200314 (Fax)

Website links


QRxPharma Limited is Australia-based a specialty pharmaceutical company and has been focused on the development and commercialisation of new treatments for pain management and abuse prevention products. The Company’s Dual Opioid platform technology – a patented fixed-ratio combination of morphine and oxycodone – provides effective analgesia with the potential to decrease clinically important opioid-related side effects, in particular respiratory depression. QRxPharma has four complementary pain management product formulations in late and early stage clinical development including: Moxduo IR, an immediate release oral capsule for acute pain; an abuse deterrent formulation of Moxduo IR, Moxduo CR, a controlled release oral tablet for chronic pain; and Moxduo IV, an intravenous formulation for moderate to severe hospital-based pain. On August 14, 2014, the Company announced that it is halting all further development work on the Moxduo portfolio of products.

Officers and directors

Edward M. Rudnic Ph.D. Chief Executive Officer
Chris J. Campbell Chief Financial Officer, Company Secretary
Age: 49
Beth A. Burnside Senior Vice President -Regulatory Affairs & Compliance
M. Janette Dixon Vice President - Global Business Development